Weight change trends and overall survival in United States veterans with follicular lymphoma treated with chemotherapy.
Understanding weight change patterns in follicular lymphoma (FL) may be important for the assessment of prognosis as well as the long-term care of survivors. A retrospective cohort of United States veterans with a new diagnosis of FL between October 1, 1998 and September 30, 2010 was assembled. Weight changes were evaluated before, during, and after treatment in 896 FL patients who received cyclophosphamide, doxorubicin, vincristine, and prednisone, with or without rituximab (CHOP ± R); cyclophosphamide, vincristine, and prednisone, with or without rituximab (CVP ± R); or rituximab monotherapy. Weight decreased an average of 1.4 kg during therapy, and >5% weight loss during this time period was associated with worse overall survival. Weight increased to an average of 1.4 kg above baseline by 24 months after treatment initiation, with 15% gaining greater than 10% of their baseline weight. Weight management strategies may be an important part of long-term survivorship planning.
a Research Service , St. Louis Veterans Affairs Medical Center , St. Louis , MO , USA.|b Department of Internal Medicine , Washington University School of Medicine , St. Louis , MO , USA.
Daphne Y
DY
Xiao
a Research Service , St. Louis Veterans Affairs Medical Center , St. Louis , MO , USA.|c Division of Oncology, Department of Internal Medicine , Washington University School of Medicine , St. Louis , MO , USA.
Suhong
S
Luo
a Research Service , St. Louis Veterans Affairs Medical Center , St. Louis , MO , USA.|c Division of Oncology, Department of Internal Medicine , Washington University School of Medicine , St. Louis , MO , USA.
Katiuscia
K
O'Brian
a Research Service , St. Louis Veterans Affairs Medical Center , St. Louis , MO , USA.
Weijian
W
Liu
a Research Service , St. Louis Veterans Affairs Medical Center , St. Louis , MO , USA.|c Division of Oncology, Department of Internal Medicine , Washington University School of Medicine , St. Louis , MO , USA.|d Division of Public Health Sciences, Department of Surgery , Washington University School of Medicine , St. Louis , MO , USA.
Kenneth R
KR
Carson
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D015415:Biomarkers; D015992:Body Mass Index; D001835:Body Weight; D005260:Female; D006801:Humans; D008224:Lymphoma, Follicular / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009026:Mortality; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D016019:Survival Analysis; D014481:United States / Q000453:epidemiology; D014728:Veterans
D015415:Biomarkers
Body weight changes; lymphoma; veterans
J Clin Oncol. 2005 Aug 1;23(22):5019-26
15983392
Am J Med. 1980 Oct;69(4):491-7
7424938
Blood. 2007 Jul 15;110(2):695-708
17389762
Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):697-704
24035331
Leuk Lymphoma. 2012 Apr;53(4):569-74
21888618
Gynecol Oncol. 2007 Nov;107(2):260-5
17675142
Obes Rev. 2001 Nov;2(4):219-29
12119993
BMC Cancer. 2010 Nov 25;10:648
21108799
Blood. 2004 Sep 1;104(5):1258-65
15126323
Blood. 2006 Sep 1;108(5):1504-8
16690968
Popul Health Metr. 2006 Apr 10;4:2
16606453
Leuk Lymphoma. 2015 Jul 25;:1-7
26085202
J Clin Oncol. 2005 Mar 1;23(7):1370-8
15684320
Epidemiol Rev. 2007;29:6-28
17510091
Nutr Cancer. 2013;65(1):43-50
23368912
Anticancer Res. 1999 Nov-Dec;19(6C):5607-10
10697626
Nature. 2000 Apr 6;404(6778):635-43
10766250
N Engl J Med. 2011 Jun 23;364(25):2392-404
21696306
J Clin Oncol. 2006 Apr 1;24(10):1582-9
16575009
Circ Cardiovasc Qual Outcomes. 2011 May;4(3):363-71
21586725
Med Care. 2009 Jan;47(1):125-8
19106741
N Engl J Med. 2006 Aug 24;355(8):763-78
16926275
JAMA. 1995 Feb 8;273(6):461-5
7654270
J Clin Oncol. 2011 Aug 10;29(23 ):3194-200
21747087
J Clin Epidemiol. 1993 Oct;46(10):1075-9; discussion 1081-90
8410092
J Epidemiol Community Health. 2005 Feb;59(2):134-9
15650145
J BUON. 2010 Apr-Jun;15(2):290-6
20658724